Can a new tracer light up tumors better than standard PET scans?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent obtained prior to the performance of any study-specific procedures. * Adults aged 18 years or older. * Histologically, cytologically, or clinically confirmed malignant solid tumor. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Clinical indication for \^18F-FDG PET imaging. * No clinically significant abnormalities in physical examination, vital signs, laboratory tests, or 12-lead electrocardiogram that, in the investigator's judgment, would interfere with study participation or image interpretation. * Women of childbearing potential must have a negative pregnancy test prior to administration of the investigational radiotracer. * Participants of childbearing potential (male and female) must agree to use highly effective contraception during the study and for at least 6 months after administration of the investigational radiotracer, and must refrain from sperm or oocyte donation during this period. * Willing and able to comply with all study procedures and follow-up requirements. Exclusion Criteria: * Any concomitant disease or medical condition that, in the investigator's judgment, could compromise participant safety or interfere with image interpretation. * Concomitant medications or therapies that may affect the safety, biodistribution, radiation dosimetry, or diagnostic performance of the investigational radiotracer. * Previous anticancer treatment (including chemotherapy, radiotherapy, immunotherapy, targeted therapy, radionuclide therapy, or major surgery) without an adequate washout period, as determined by the investigator. * Known hypersensitivity to gallium-containing radiopharmaceuticals, ethanol, any component of the investigational product, or a history of severe allergic reactions. * Pregnant or breastfeeding women. * Inability to undergo PET/CT imaging or comply with study procedures. Participation in another interventional clinical trial that, in the investigator's judgment, could interfere with this study. * Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.